1
|
Kundi M. Letter to the editor. ENVIRONMENT INTERNATIONAL 2024; 187:108665. [PMID: 38677087 DOI: 10.1016/j.envint.2024.108665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Accepted: 04/15/2024] [Indexed: 04/29/2024]
Abstract
Some have looked forward to the publication of the results of the COSMOS study on brain tumors, because the potential biases from retrospective investigations predominating the search for brain tumor risks of mobile phone use since the late 1990 s were deemed unresolvable by further investigations of that type. Indeed, prospective cohort studies typically have the advantage of being not or less affected by differential exposure misclassification, recall and selection bias, and, as they proceed in the direction of the time arrow, results are more easily interpreted in terms of causation. However, results of the COSMOS study published now in this journal are not of help for the risk assessment of mobile phone use and do not support the conclusions of the authors that their findings "suggest that the cumulative amount of mobile phone use is not associated with the risk of developing glioma, meningioma, or acoustic neuroma".
Collapse
Affiliation(s)
- Michael Kundi
- Medical University Vienna, Center for Public Health, Vienna, Austria
| |
Collapse
|
2
|
Camargo A, Schneider T, Liu L, Pakpoor J, Kleinberg L, Yousem DM. Pretreatment ADC Values Predict Response to Radiosurgery in Vestibular Schwannomas. AJNR Am J Neuroradiol 2017; 38:1200-1205. [PMID: 28408629 DOI: 10.3174/ajnr.a5144] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 01/22/2017] [Indexed: 12/26/2022]
Abstract
BACKGROUND AND PURPOSE The response rate of vestibular schwannomas to radiation therapy is variable, and there are surgical options available in the event of treatment failure. The aim of this study was to determine whether pre- and posttreatment ADC values can predict the tumor response to radiation therapy. MATERIALS AND METHODS From a data base of 162 patients with vestibular schwannomas who underwent radiation therapy with gamma knife, CyberKnife, or fractionated stereotactic radiation therapy as the first-line therapy between January 2003 and December 2013, we found 20 patients who had pretreatment ADC values. There were 108 patients (including these 20) had serial MR images that included DWI allowing calculated ADC values from 2-132 months after radiation therapy. Two reviewers measured the mean, minimum, and maximum ADC values from elliptical ROIs that included tumor tissue only. Treatment responders were defined as those with a tumor total volume shrinkage of 20% or more after radiation therapy. RESULTS The pretreatment mean minimum ADC for nonresponders was 986.7 × 10-6 mm2/s (range, 844-1230 × 10-6 mm2/s) and it was 669.2 × 10-6 mm2/s (range, 345-883 × 10-6 mm2/s) for responders. This difference was statistically significant (P < .001). Using a minimum ADC value of 800 × 10-6 mm2/s led to the correct classification of 18/20 patients based on pretreatment ADC values. The intraclass correlation between reviewers was 0.61. No posttreatment ADC values predicted response. CONCLUSIONS Pretreatment ADC values of vestibular schwannomas are lower in responders than nonresponders. Using a minimum ADC value of 800 × 10-6 mm2/s correctly classified 90% of cases.
Collapse
Affiliation(s)
- A Camargo
- From the Division of Neuroradiology and Russell H. Morgan Department of Radiology and Radiological Science (A.C., L.L., J.P., D.M.Y.)
| | - T Schneider
- the Department of Diagnostic and Interventional Neuroradiology (T.S.), University Medical Center Hamburg-Eppendorf, Hamburg Germany
| | - L Liu
- From the Division of Neuroradiology and Russell H. Morgan Department of Radiology and Radiological Science (A.C., L.L., J.P., D.M.Y.)
| | - J Pakpoor
- From the Division of Neuroradiology and Russell H. Morgan Department of Radiology and Radiological Science (A.C., L.L., J.P., D.M.Y.)
| | - L Kleinberg
- Department of Radiation Oncology (L.K.), Johns Hopkins Medical Institutions, Baltimore, Maryland
| | - D M Yousem
- From the Division of Neuroradiology and Russell H. Morgan Department of Radiology and Radiological Science (A.C., L.L., J.P., D.M.Y.)
| |
Collapse
|
3
|
Paldor I, Chen AS, Kaye AH. Growth rate of vestibular schwannoma. J Clin Neurosci 2016; 32:1-8. [PMID: 27450283 DOI: 10.1016/j.jocn.2016.05.003] [Citation(s) in RCA: 90] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Accepted: 05/15/2016] [Indexed: 11/30/2022]
Abstract
Vestibular schwannoma (VS) is the most common tumor in the extra-axial posterior fossa compartment in adults. Growth rate is paramount to decision making regarding treatment and follow up of these tumors. We conducted a comprehensive review of the literature to answer four questions: What percentage of newly diagnosed VS will grow on follow-up? What factors correlate to tumor growth? What is the "normal" growth rate for sporadic VS? What factors characterize VS with rapid growth? Thirty-seven reports, with more than 4000 patients, fit our review criteria. One third of newly diagnosed VS will grow on follow-up of 1-3years. However, after 5years, up to one half will grow. Patient age and sex do not influence growth of VS. Hearing loss and vertigo at presentation do not predict tumor growth. It is unclear whether balance disturbance or tinnitus predict tumor growth. Tumor size and location do not predict tumor growth. Growth in the first year of observation is a strong predictor of tumor growth. The average growth rate of a VS is 0.99-1.11mm/year. However, the expected growth rate for VS that have been shown to grow at first follow-up is 3mm/year. Factors that may predict tumor growth of above 4mm/year are cystic and hemorrhagic features in the tumor, and hormonal treatment. VS grow at an average 1mm/year. VS that have been shown to grow at first follow-up should be considered for treatment, unless contraindicated. Long term follow-up is recommended for VS.
Collapse
Affiliation(s)
- Iddo Paldor
- Department of Neurosurgery, The Royal Melbourne Hospital, 300 Grattan street, Parkville, Victoria 3052, Australia.
| | - Annie S Chen
- Department of Neurosurgery, The Royal Melbourne Hospital, 300 Grattan street, Parkville, Victoria 3052, Australia
| | - Andrew H Kaye
- Department of Surgery, The University of Melbourne, Parkville, Australia
| |
Collapse
|
4
|
Romani R, Pollock J. Spontaneous shrinkage of vestibular schwannoma. Surg Neurol Int 2016; 7:59. [PMID: 27280055 PMCID: PMC4882965 DOI: 10.4103/2152-7806.182740] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Accepted: 04/10/2016] [Indexed: 11/07/2022] Open
Abstract
Background: “Watch, wait, and rescan” (WWR) has an established place as a successful management option for a significant proportion of vestibular schwannomas (VS) as an alternative to microsurgical removal or stereotactic radiotherapy. VS may grow slowly and continuously, followed by stagnation or even shrinkage. We present two case reports of spontaneous shrinkage of VS along with a review of the literature. Case Description: A 29-year-old female presented with a progressive history of visual blurring and intermittent diplopia over 2 months. A 29 mm of maximum intracranial diameter (ICD) VS with secondary obstructive hydrocephalus was diagnosed. The patient underwent a ventriculo-peritoneal shunt with resolution of her symptoms and opted for initial WWR management. Interval scanning between 2007 and 2014 showed progressive reduction in the maximum ICD together with reduction in the degree of central tumor enhancement. Maximum ICD at most recent follow up was 22 mm. A 28-year-old female was referred with right sensorineural deafness. A right VS of maximum ICD of 27 mm was diagnosed. Initial WWR management was planned after discussion. Serial imaging showed an initial increase in the size of the tumor followed by progressive reduction in size. The most recent follow up showed a maximum ICD of 20 mm. Conclusion: Early WWR management can be associated with spontaneous shrinkage of VS over time. Prospective clinical study of larger numbers of such cases using the UK VS database may help to identify predictive factors for the spontaneous regression of VS.
Collapse
Affiliation(s)
- Rossana Romani
- Department of Neurosurgery, Queen's Hospital, Essex Neuroscience Centre, Romford, London, UK
| | - Jonathan Pollock
- Department of Neurosurgery, Queen's Hospital, Essex Neuroscience Centre, Romford, London, UK
| |
Collapse
|
5
|
Jethanamest D, Rivera AM, Ji H, Chokkalingam V, Telischi FF, Angeli SI. Conservative management of vestibular schwannoma: Predictors of growth and hearing. Laryngoscope 2015; 125:2163-8. [DOI: 10.1002/lary.25159] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/18/2014] [Indexed: 11/07/2022]
Affiliation(s)
- Daniel Jethanamest
- Department of Otolaryngology; New York University School of Medicine; New York New York
| | - Andrew M. Rivera
- Department of Otolaryngology; University of Miami Miller School of Medicine; Miami Florida U.S.A
| | - Hongzhao Ji
- Department of Otolaryngology; University of Miami Miller School of Medicine; Miami Florida U.S.A
| | | | - Fred F. Telischi
- Department of Otolaryngology; University of Miami Miller School of Medicine; Miami Florida U.S.A
| | - Simon I. Angeli
- Department of Otolaryngology; University of Miami Miller School of Medicine; Miami Florida U.S.A
| |
Collapse
|
6
|
Larjani S, Monsalves E, Pebdani H, Krischek B, Gentili F, Cusimano M, Laperriere N, Hayhurst C, Zadeh G. Identifying predictors of early growth response and adverse radiation effects of vestibular schwannomas to radiosurgery. PLoS One 2014; 9:e110823. [PMID: 25337892 PMCID: PMC4206429 DOI: 10.1371/journal.pone.0110823] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Accepted: 09/23/2014] [Indexed: 01/09/2023] Open
Abstract
PURPOSE To determine whether pre-treatment growth rate of vestibular schwannomas (VS) predict response to radiosurgery. METHODS A retrospective review of a prospectively maintained database of all VS patients treated with 12Gy prescription dose between September 2005 and June 2011 at our institution using the Leksell Model 4C Gamma Knife Unit was conducted. Patients who had a minimum of 12-months clinical and radiological assessment before and after radiosurgery were included in this study. Tumor growth rates were calculated using specific growth rate (SGR). Tumor volumes were measured on FIESTA-MRI scans using ITK-SNAP v2.2. RESULTS Following radiosurgery, twenty-seven (42.9%) patients showed a significant decrease in volume after one year, twenty-nine (46.0%) stabilized, and seven (11.1%) continued to grow. There was no correlation between VS pre-treatment SGRs with post-treatment SGRs (p = 0.34), and incidence of adverse radiation effects (ARE). The reduction in tumors' SGRs after radiosurgery was proportional to pre-treatment SGRs, although this correlation was not statistically significant (p = 0.19). Analysis of risk factors revealed a positive correlation between post-treatment SGRs and incidence of non-auditory complications, most of which were attributed to ARE (p = 0.047). CONCLUSION Pre-treatment growth rate of VS does not predict tumor response to radiosurgery or incidence of ARE. VS with higher SGRs post-radiosurgery are more likely to experience ARE.
Collapse
Affiliation(s)
- Soroush Larjani
- Department of Neurosurgery, University Health Network, Toronto, Canada
- * E-mail: (SL); (GZ)
| | - Eric Monsalves
- Department of Neurosurgery, University Health Network, Toronto, Canada
| | - Houman Pebdani
- Department of Neurosurgery, University Health Network, Toronto, Canada
| | - Boris Krischek
- Department of Neurosurgery, University Health Network, Toronto, Canada
| | - Fred Gentili
- Department of Neurosurgery, University Health Network, Toronto, Canada
| | - Michael Cusimano
- Department of Neurosurgery, St. Michael's Hospital, Toronto, Canada
| | | | - Caroline Hayhurst
- Department of Neurosurgery, The Walton Centre, Liverpool, United Kingdom
| | - Gelareh Zadeh
- Department of Neurosurgery, University Health Network, Toronto, Canada
- * E-mail: (SL); (GZ)
| |
Collapse
|
7
|
Spontaneous tumour shrinkage in 1261 observed patients with sporadic vestibular schwannoma. The Journal of Laryngology & Otology 2013; 127:739-43. [DOI: 10.1017/s0022215113001266] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
AbstractObjective:To determine the rate of spontaneous tumour shrinkage in a group of patients with sporadic vestibular schwannoma managed with a ‘wait and scan’ approach.Patients:All patients with a unilateral cerebello-pontine angle tumour resembling a vestibular schwannoma were registered prospectively in a national database in Denmark. Patients registered with tumour shrinkage were identified and all computed tomography and magnetic resonance imaging scans retrieved, re-evaluated and related to the clinical data.Results:Of 1261 observed patients, 48 displayed spontaneous shrinkage (3.81 per cent). Mean absolute shrinkage was 6.25 mm, equivalent to 52.1 per cent. Absolute shrinkage correlated with tumour size and follow-up period, whereas relative shrinkage was significantly greater for tumours which were purely intrameatal at diagnosis. There was no correlation between age and the degree of shrinkage.Conclusion:Four per cent of sporadic vestibular schwannomas shrink spontaneously. These findings substantiate the ‘wait and scan’ strategy for tumours with a largest extrameatal diameter of up to 20 mm.
Collapse
|
8
|
Huang X, Caye-Thomasen P, Stangerup SE. Distinct spontaneous shrinkage of a sporadic vestibular schwannoma. Auris Nasus Larynx 2013; 40:243-6. [DOI: 10.1016/j.anl.2012.01.011] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2011] [Revised: 01/13/2012] [Accepted: 04/06/2012] [Indexed: 10/28/2022]
|
9
|
Hardell L, Carlberg M, Hansson Mild K. Use of mobile phones and cordless phones is associated with increased risk for glioma and acoustic neuroma. ACTA ACUST UNITED AC 2012; 20:85-110. [PMID: 23261330 DOI: 10.1016/j.pathophys.2012.11.001] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Revised: 11/14/2012] [Accepted: 11/15/2012] [Indexed: 12/20/2022]
Abstract
The International Agency for Research on Cancer (IARC) at WHO evaluation of the carcinogenic effect of RF-EMF on humans took place during a 24-31 May 2011 meeting at Lyon in France. The Working Group consisted of 30 scientists and categorised the radiofrequency electromagnetic fields from mobile phones, and from other devices that emit similar non-ionising electromagnetic fields (RF-EMF), as Group 2B, i.e., a 'possible', human carcinogen. The decision on mobile phones was based mainly on the Hardell group of studies from Sweden and the IARC Interphone study. We give an overview of current epidemiological evidence for an increased risk for brain tumours including a meta-analysis of the Hardell group and Interphone results for mobile phone use. Results for cordless phones are lacking in Interphone. The meta-analysis gave for glioma in the most exposed part of the brain, the temporal lobe, odds ratio (OR)=1.71, 95% confidence interval (CI)=1.04-2.81 in the ≥10 years (>10 years in the Hardell group) latency group. Ipsilateral mobile phone use ≥1640h in total gave OR=2.29, 95% CI=1.56-3.37. The results for meningioma were OR=1.25, 95% CI=0.31-4.98 and OR=1.35, 95% CI=0.81-2.23, respectively. Regarding acoustic neuroma ipsilateral mobile phone use in the latency group ≥10 years gave OR=1.81, 95% CI=0.73-4.45. For ipsilateral cumulative use ≥1640h OR=2.55, 95% CI=1.50-4.40 was obtained. Also use of cordless phones increased the risk for glioma and acoustic neuroma in the Hardell group studies. Survival of patients with glioma was analysed in the Hardell group studies yielding in the >10 years latency period hazard ratio (HR)=1.2, 95% CI=1.002-1.5 for use of wireless phones. This increased HR was based on results for astrocytoma WHO grade IV (glioblastoma multiforme). Decreased HR was found for low-grade astrocytoma, WHO grades I-II, which might be caused by RF-EMF exposure leading to tumour-associated symptoms and earlier detection and surgery with better prognosis. Some studies show increasing incidence of brain tumours whereas other studies do not. It is concluded that one should be careful using incidence data to dismiss results in analytical epidemiology. The IARC carcinogenic classification does not seem to have had any significant impact on governments' perceptions of their responsibilities to protect public health from this widespread source of radiation.
Collapse
Affiliation(s)
- Lennart Hardell
- Department of Oncology, University Hospital, SE-701 85 Örebro, Sweden.
| | | | | |
Collapse
|
10
|
Oishi K, Itamoto T, Okimoto S, Nishisaka T. Multiple retroperitoneal schwannomas mimicking adrenal tumors. Case Rep Oncol 2012; 5:222-8. [PMID: 22679427 PMCID: PMC3369249 DOI: 10.1159/000338973] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Schwannomas are benign tumors mostly arising from the head and neck. Retroperitoneal schwannomas are rare. Here we report the case of a 68-year-old woman with multiple retroperitoneal schwannomas. An abdominal computed tomography (CT) scan showed 1 non-enhancing mass with a low-density area, 4.6 cm in diameter, in the left adrenal region and another non-enhancing mass with a low-density area, 2.9 cm in diameter, in the para-aortic region. The patient had regularly undergone CT scans for malignant tumor screening in maintenance dialysis patients. Retrospectively, the 2 tumors had existed in the same regions in previous CT scans and had gradually increased in size. The tumors were completely resected. Pathological diagnosis of both tumors was schwannoma. When a CT scan shows a slowly growing retroperitoneal tumor with a low-density area, schwannoma should be considered. If the tumor increases in size, complete resection should be performed for pathological diagnosis.
Collapse
Affiliation(s)
- Koichi Oishi
- Departments of Surgery and Hiroshima Prefectural Hospital, Hiroshima, Japan
| | | | | | | |
Collapse
|
11
|
Varughese JK, Breivik CN, Wentzel-Larsen T, Lund-Johansen M. Growth of untreated vestibular schwannoma: a prospective study. J Neurosurg 2012; 116:706-12. [DOI: 10.3171/2011.12.jns111662] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object
Small vestibular schwannomas (VSs) are often conservatively managed and treated only upon growth. Growth is usually reported in mm/year, but describing the growth of a 3D structure by a single diameter has been questioned. As a result, VS growth dynamics should be further investigated. In addition, baseline clinical parameters that could predict growth would be helpful. In this prospective study the authors aimed to describe growth dynamics in a cohort of conservatively managed VSs. They also compared different growth models and evaluated the ability of baseline parameters to predict future growth.
Methods
Between 2000 and 2006, 178 consecutive patients with unilateral de novo small-sized VSs identified among the Norwegian population of 4.8 million persons were referred to a tertiary care center and were included in a study protocol of conservative management. Tumor size was defined by MR imaging–based volume estimates and was recorded along with clinical data at regular visits. Mixed-effects models were used to analyze the relationships between observations. Three growth models were compared using statistical diagnostic tests: a mm/year–based model, a cm3/year–based model, and a volume doubling time (VDT)-based model. A receiver operating characteristic curve analysis was used to determine a cutoff for the VDT-based model for distinguishing growing and nongrowing tumors.
Results
A mean growth rate corresponding to a VDT of 4.40 years (95% CI 3.49–5.95) was found. Other growth models in this study revealed mean growth rates of 0.66 mm/year (95% CI 0.47–0.86) and 0.19 cm3/year (95% CI 0.12–0.26). Volume doubling time was found to be the most realistic growth model. All baseline variables had p values > 0.09 for predicting growth.
Conclusions
Based on the actual measurements, VDT was the most correct way to describe VS growth. The authors found that a cutoff of 5.22 years provided the best value to distinguish growing from nongrowing tumors. None of the investigated baseline predictors were usable as predictors of growth.
Collapse
Affiliation(s)
| | | | - Tore Wentzel-Larsen
- 3Centre for Clinical Research, Haukeland University Hospital, Bergen
- 4Centre for Child and Adolescent Mental Health, Eastern and Southern Norway; and
- 5Norwegian Centre for Violence and Traumatic Stress Studies, Oslo, Norway
| | - Morten Lund-Johansen
- 1Institute of Surgical Sciences, University of Bergen
- 2Department of Neurosurgery, and
| |
Collapse
|
12
|
Lee JD, Kwon TJ, Kim UK, Lee WS. Genetic and epigenetic alterations of the NF2 gene in sporadic vestibular schwannomas. PLoS One 2012; 7:e30418. [PMID: 22295085 PMCID: PMC3266248 DOI: 10.1371/journal.pone.0030418] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2011] [Accepted: 12/15/2011] [Indexed: 12/11/2022] Open
Abstract
Background Mutations in the neurofibromatosis type 2 (NF2) tumor-suppressor gene have been identified in not only NF2-related tumors but also sporadic vestibular schwannomas (VS). This study investigated the genetic and epigenetic alterations in tumors and blood from 30 Korean patients with sporadic VS and correlated these alterations with tumor behavior. Methodology/Principal Findings NF2 gene mutations were detected using PCR and direct DNA sequencing and three highly polymorphic microsatellite DNA markers were used to assess the loss of heterozygosity (LOH) from chromosome 22. Aberrant hypermethylation of the CpG island of the NF2 gene was also analyzed. The tumor size, the clinical growth index, and the proliferative activity assessed using the Ki-67 labeling index were evaluated. We found 18 mutations in 16 cases of 30 schwannomas (53%). The mutations included eight frameshift mutations, seven nonsense mutations, one in-frame deletion, one splicing donor site, and one missense mutation. Nine patients (30%) showed allelic loss. No patient had aberrant hypermethylation of the NF2 gene and correlation between NF2 genetic alterations and tumor behavior was not observed in this study. Conclusions/Significance The molecular genetic changes in sporadic VS identified here included mutations and allelic loss, but no aberrant hypermethylation of the NF2 gene was detected. In addition, no clear genotype/phenotype correlation was identified. Therefore, it is likely that other factors contribute to tumor formation and growth.
Collapse
Affiliation(s)
- Jong Dae Lee
- Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang University College of Medicine, Bucheon, Korea
| | - Tae Jun Kwon
- Department of Biology, College of Natural Sciences, Kyungpook National University, Daegu, Korea
| | - Un-Kyung Kim
- Department of Biology, College of Natural Sciences, Kyungpook National University, Daegu, Korea
- * E-mail:
| | - Won-Sang Lee
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea
| |
Collapse
|
13
|
Kapoor S, Batra S, Carson K, Shuck J, Kharkar S, Gandhi R, Jackson J, Wemmer J, Terezakis S, Shokek O, Kleinberg L, Rigamonti D. Long-term outcomes of vestibular schwannomas treated with fractionated stereotactic radiotherapy: an institutional experience. Int J Radiat Oncol Biol Phys 2010; 81:647-53. [PMID: 20884130 DOI: 10.1016/j.ijrobp.2010.06.006] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2010] [Revised: 04/20/2010] [Accepted: 06/07/2010] [Indexed: 11/29/2022]
Abstract
PURPOSE We assessed clinical outcome and long-term tumor control after fractionated stereotactic radiotherapy (FSRT) for unilateral schwannoma. METHODS AND MATERIALS Between 1995 and 2007, 496 patients were treated with fractionated stereotactic radiotherapy at Johns Hopkins Hospital (Baltimore, MD); 385 patients had radiologic follow-up that met the inclusion criteria. The primary endpoint was treatment failure. Secondary endpoints were radiologic progression and clinical outcome. Logistic regression analysis assessed the association of age, race, tumor side, sex, and pretreatment symptoms. RESULTS In 11 patients (3%) treatment failed, and they required salvage (microsurgical) treatment. Radiologic progression was observed in 116 patients (30.0%), including 35 patients (9%) in whom the treatment volume more than doubled during the follow-up period, although none required surgical resection. Tumors with baseline volumes of less than 1 cm(3) were 18.02 times more likely to progress than those with tumor volumes of 1 cm(3) or greater (odds ratio, 18.02; 95% confidence interval, 4.25-76.32). Treatment-induced neurologic morbidity included 8 patients (1.6%) with new facial weakness, 12 patients (2.8%) with new trigeminal paresthesias, 4 patients (0.9%) with hydrocephalus (1 communicating and 3 obstructive), and 2 patients (0.5%) with possibly radiation-induced neoplasia. CONCLUSIONS Although the rate of treatment failure is low (3%), careful follow-up shows that radiologic progression occurs frequently. When reporting outcome, the "no salvage surgery needed" and "no additional treatment needed" criteria for treatment success need to be complemented by the radiologic data.
Collapse
Affiliation(s)
- Sumit Kapoor
- Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Kundi M. The controversy about a possible relationship between mobile phone use and cancer. CIENCIA & SAUDE COLETIVA 2010; 15:2415-30. [DOI: 10.1590/s1413-81232010000500016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Over the last decade, mobile phone use increased to almost 100% prevalence in many countries. Evidence for potential health hazards accumulated in parallel by epidemiologic investigations has raised controversies about the appropriate interpretation and the degree of bias and confounding responsible for reduced or increased risk estimates. Overall, 33 epidemiologic studies were identified in the peer-reviewed literature, mostly (25) about brain tumors. Methodologic considerations revealed that three important conditions for epidemiologic studies to detect an increased risk are not met:no evidence-based exposure metric is available; the observed duration of mobile phone use is generally still too low; no evidence-based selection of end points among the grossly different types of neoplasias is possible because of lack of etiologic hypotheses. The overall evidence speaks in favor of an increased risk, but its magnitude cannot be assessed at present because of insufficient information on long-term use.
Collapse
|
15
|
Tan M, Myrie OA, Lin FR, Niparko JK, Minor LB, Tamargo RJ, Francis HW. Trends in the management of vestibular schwannomas at Johns Hopkins 1997-2007. Laryngoscope 2010; 120:144-9. [PMID: 19877188 DOI: 10.1002/lary.20672] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVES/HYPOTHESIS To assess trends in the management of unilateral vestibular schwannomas over an 11-year period and to identify disease- and provider-related influences. STUDY DESIGN Retrospective chart review. METHODS Subjects presented to the Department of Otolaryngology-Head and Neck Surgery and the Department of Neurosurgery for management of unilateral vestibular schwannoma from 1997 through 2007, with at least two visits within the first year of presentation. The proportion of patients for whom initial management consisted of observation, surgical resection, or radiation therapy was determined, and the relative influence of study year, patient age, hearing status, and tumor size was analyzed. RESULTS Over the study period there was an increase in the proportion of cases that were observed with follow-up scanning (10.5% to 28.0%) and recommended for radiation (0% to 4.0%), whereas the proportion of operated cases declined (89.5% to 68.0%). There were no changes in mean age or hearing status at diagnosis, but mean tumor size declined significantly. Compared to those undergoing surgery, patients choosing observation and radiation therapy were on average 11.7 and 4.5 years older, respectively. Tumors that were surgically removed were on average 11.6 mm larger than those that were observed. The increasing frequency over time of observation relative to surgery was significant even after controlling for age, hearing status, and tumor size. CONCLUSIONS Among patients managed by our center, there has been a significant shift in management of vestibular schwannomas over the last decade, with increasing tendency towards observation. This trend implies changing provider philosophy and patient expectations.
Collapse
Affiliation(s)
- Marietta Tan
- Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland 21287, USA
| | | | | | | | | | | | | |
Collapse
|
16
|
Vestibular schwannoma: role of conservative management. The Journal of Laryngology & Otology 2009; 124:251-7. [DOI: 10.1017/s0022215109992362] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
AbstractObjective:To assess the outcome of conservative management of vestibular schwannoma.Study design:Observational study.Setting:Tertiary referral centre.Patients:Four hundred and thirty-six patients with vestibular schwannoma (490 tumours), including 327 sporadic tumours and 163 tumours in 109 patients with neurofibromatosis type two.Main outcome measures:The relationship of tumour growth to tumour size at presentation, and to certain demographic features.Results:The initial tumour size was significantly larger in the neurofibromatosis type two group (11 mm) than in the sporadic vestibular schwannoma group (5.1 mm). In both groups, 68 per cent of tumours did not grow during follow up (mean 3.6 years; range one to 14 years). The mean growth rate was 1.1 mm/year (range 0–15 mm/year) for sporadic tumours and 1.7 mm/year (range 0–18 mm/year) for neurofibromatosis type two tumours. The tumour growth rate correlated positively with tumour size in the sporadic tumour group, and correlated negatively with age in the neurofibromatosis type two group.Conclusion:Two-thirds of vestibular schwannomas did not grow. Radiological surveillance is an acceptable approach in carefully selected patients. Once a sporadic vestibular schwannoma reaches 2 cm in intracranial diameter, it is likely to continue growing. We do not recommend conservative management for sporadic tumours with an intracranial diameter of 1.5 cm or more. Vestibular schwannoma management is more complex in patients with neurofibromatosis type two.
Collapse
|
17
|
Clinical, Radiographic, and Audiometric Predictors in Conservative Management of Vestibular Schwannoma. Otol Neurotol 2009; 30:507-14. [DOI: 10.1097/mao.0b013e31819d3465] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Bakkouri WE, Kania RE, Guichard JP, Lot G, Herman P, Huy PTB. Conservative management of 386 cases of unilateral vestibular schwannoma: tumor growth and consequences for treatment. J Neurosurg 2009; 110:662-9. [DOI: 10.3171/2007.5.16836] [Citation(s) in RCA: 151] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
ObjectThe object of this study was to evaluate the natural history, pattern, and occurrence of tumor growth and its consequences for treatment of small-sized vestibular schwannomas (VSs).MethodsFrom 1990 to 2005, 386 patients underwent conservative management for VS because of the following: age > 60 years, poor health/medical risks, risk of deterioration of good hearing, small tumor size, minimal or no incapacitating symptoms, and/or patient preference. Tumor size was measured by MR imaging according to the guidelines of the Committee on Hearing and Equilibrium. The first MR imaging study was performed 1 year after diagnosis, and subsequent imaging was performed yearly or every 2 years depending on the appearance of new symptoms, tumor growth, or both.ResultsSixty-one patients were lost to follow-up the first year after presentation. Of the 325 patients for whom 1-year follow-up data were available, 39 showed tumor growth ≥ 3 mm. Conservative management was discontinued for these 39 patients. The patients who returned for follow-up were evaluated at 1- or 2-year intervals depending on tumor growth. The authors extrapolated to obtain data for 2-year intervals, yielding data for 160, 56, 21, and 8 patients at 3, 5, 7, and 9 years after initial presentation, respectively. The overall mean tumor growth rate (±standard deviation) was 1.15 ± 2.4 mm/year. This rate was estimated by pooling all values of tumor growth that had been determined for all patients and dividing by the total number of “events,” with each assessment constituting an event. In 58.6% of patients, the annual tumor growth rate was < 1 mm/year; in 29.2%, 1–3 mm/year; and in 12.2%, ≥ 3 mm/ year. The growth rates of intrameatal (1.02 ± 1.8 mm/year) and extrameatal (1.40 ± 3.1 mm/year) tumors did not differ significantly. No significant association was found between tumor growth rate and sex, age, initial hearing status, or initial tumor grade. Delay in diagnosis was the only significant factor associated with tumor growth rate. During follow-up, conservative management was discontinued for 77 (23.7%) of the 325 patients for whom at least 12-month follow-up data were available; surgery was performed in 60 (77.9%) and radiation therapy in 17 (22.1%).ConclusionsThe results of this study support the role of a conservative “wait-and-scan” policy of management for small-sized VSs because most have a slow growth rate. Long-term neuroimaging follow-up is needed even with non-growing tumors.
Collapse
Affiliation(s)
- Wissame El Bakkouri
- 1Departments of Otorhinolaryngology–Head and Neck Surgery, Laboratoire de Neurobiologie et des Réseaux Sensorimoteurs, LNRS CNRS 7060
| | - Romain E. Kania
- 1Departments of Otorhinolaryngology–Head and Neck Surgery, Laboratoire de Neurobiologie et des Réseaux Sensorimoteurs, LNRS CNRS 7060
| | | | - Guillaume Lot
- 3Neurosurgery, Lariboisière Hospital, University of Paris 7–Denis Diderot, Paris, France
| | - Philippe Herman
- 1Departments of Otorhinolaryngology–Head and Neck Surgery, Laboratoire de Neurobiologie et des Réseaux Sensorimoteurs, LNRS CNRS 7060
| | - Patrice Tran Ba Huy
- 1Departments of Otorhinolaryngology–Head and Neck Surgery, Laboratoire de Neurobiologie et des Réseaux Sensorimoteurs, LNRS CNRS 7060
| |
Collapse
|
19
|
Kundi M. The controversy about a possible relationship between mobile phone use and cancer. ENVIRONMENTAL HEALTH PERSPECTIVES 2009; 117:316-24. [PMID: 19337502 PMCID: PMC2661897 DOI: 10.1289/ehp.11902] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2008] [Accepted: 09/26/2008] [Indexed: 05/13/2023]
Abstract
OBJECTIVE During the last decade, mobile phone use increased to almost 100% prevalence in many countries of the world. Evidence for potential health hazards accumulated in parallel by epidemiologic investigations has raised controversies about the appropriate interpretation and the degree of bias and confounding responsible for reduced or increased risk estimates. DATA SOURCES Overall, I identified 33 epidemiologic studies in the peer-reviewed literature, most of which (25) were about brain tumors. Two groups have collected data for >or=10 years of mobile phone use: Hardell and colleagues from Sweden and the Interphone group, an international consortium from 13 countries coordinated by the International Agency for Research on Cancer. DATA SYNTHESIS Combined odds ratios (95% confidence intervals) from these studies for glioma, acoustic neuroma, and meningioma were 1.5 (1.2-1.8); 1.3 (0.95-1.9); and 1.1 (0.8-1.4), respectively. CONCLUSIONS Methodologic considerations revealed that three important conditions for epidemiologic studies to detect an increased risk are not met: a ) no evidence-based exposure metric is available; b) the observed duration of mobile phone use is generally still too low; c) no evidence-based selection of end points among the grossly different types of neoplasias is possible because of lack of etiologic hypotheses. Concerning risk estimates, selection bias, misclassification bias, and effects of the disease on mobile phone use could have reduced estimates, and recall bias may have led to spuriously increased risks. The overall evidence speaks in favor of an increased risk, but its magnitude cannot be assessed at present because of insufficient information on long-term use.
Collapse
Affiliation(s)
- Michael Kundi
- Institute of Environmental Health, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
20
|
Myrseth E, Pedersen PH, Møller P, Lund-Johansen M. Treatment of vestibular schwannomas. Why, when and how? Acta Neurochir (Wien) 2007; 149:647-60; discussion 660. [PMID: 17558460 DOI: 10.1007/s00701-007-1179-0] [Citation(s) in RCA: 89] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2006] [Accepted: 02/08/2007] [Indexed: 01/22/2023]
Abstract
Sporadic vestibular schwannoma (VS) causes unilateral hearing loss, tinnitus, vertigo and unsteadiness. In many cases, the tumour size may remain unchanged for many years following diagnosis, which is typically made by MRI. In the majority of cases the tumour is small, leaving the clinician and patient with the options of either serial scanning or active treatment by gamma knife radiosurgery (GKR) or microneurosurgery. Despite the vast number of published treatment reports, comparative studies are few, and evidence is no better than class III (May, 2006). The predominant clinical endpoints of VS treatment include tumour control, facial nerve function and hearing preservation. Less focus has been put on symptom relief and health-related quality of life (QOL). It is uncertain if treating a small tumour leaves the patient with a better chance of obtaining relief from future hearing loss, vertigo or tinnitus than by observing it without treatment. Recent data indicate that QOL is reduced in untreated VS patients, and may differ between patients who have been operated and patients treated with GKR. In the present paper we review the natural course and complaints of untreated VS patients, and the treatment alternatives and results. Furthermore, we review the literature concerning quality of life in patients with VS. Finally, we present our experience with a management strategy applied to more than 300 cases since 2001.
Collapse
Affiliation(s)
- E Myrseth
- Department of Neurosurgery, Institute of Surgical Science, Haukeland University Hospital, University of Bergen, Bergen, Norway.
| | | | | | | |
Collapse
|
21
|
Lassaletta L, Bello MJ, Del Río L, Alfonso C, Roda JM, Rey JA, Gavilan J. DNA Methylation of Multiple Genes in Vestibular Schwannoma. Otol Neurotol 2006; 27:1180-5. [PMID: 16983315 DOI: 10.1097/01.mao.0000226291.42165.22] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
HYPOTHESIS The purpose of this study was to examine the DNA methylation profile of several genes in a series of vestibular schwannomas, and to analyze its relationship with clinical and radiological features. BACKGROUND Aberrant methylation of promoter regions is a major mechanism for silencing of tumor suppressor genes in several tumors. There is limited information about methylation status in vestibular schwannoma, with no clinical or radiological implications described to date. METHODS The methylation status of 16 tumor-related genes including RASSF1A, RAR-B, VHL, PTEN, HMLH1, RB1, TP16, CASP8, ER, TIMP3, MGMT, DAPK, TP73, GSTP1, TP14, and THBS1 was examined in a series of 22 vestibular schwannomas.The bisulfite modification of genomic DNA was performed. Clinical and radiological features were compared with the methylation results. RESULTS Methylation values from 9% to 27% were found in 12 of 16 genes tested, including RASSF1A, VHL, PTEN, TP16, CASP8, TIMP3, MGMT, DAPK, THBS1, HMLH1, TP73, and GSTP1. A significant association was found between CASP8 and RASSF1A methylation. Methylation of CASP8 was associated with the patient's age and the tumor size. Methylation of TP73 was associated with hearing loss. RASSF1A methylation was inversely correlated with the clinical growth index. CONCLUSION Aberrant methylation of tumor-related genes may play a role in the development of vestibular schwannomas. Our results may provide useful clues to the development of prognostic assays for these tumors.
Collapse
Affiliation(s)
- Luis Lassaletta
- Department of Otolaryngology, Laboratorio Oncogenetica Molecular, La Paz University Hospital, Madrid, Spain.
| | | | | | | | | | | | | |
Collapse
|
22
|
Diensthuber M, Lenarz T, Stöver T. Determination of the clinical growth index in unilateral vestibular schwannoma. Skull Base 2006; 16:31-8. [PMID: 16880899 PMCID: PMC1408073 DOI: 10.1055/s-2005-922098] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVES To analyze factors associated with the clinical growth index of sporadic unilateral vestibular schwannoma and to evaluate the validity of the index as an indicator of tumor growth. DESIGN A retrospective case review study. PATIENTS AND METHODS A series of 118 patients with unilateral vestibular schwannomas. Clinical growth index was calculated by dividing tumor size by the length of clinical history. Clinical growth index, tumor size, symptoms, and symptom duration were tested for a relationship with tumor location, patient sex, and age. All tests were performed for the total group and separately for three subgroups: intrameatal tumors (IT group, n = 46), intrameatal and extrameatal tumors (IET group, n = 60), and extrameatal tumors (ET group, n = 12). RESULTS Vestibular schwannoma diameter ranged from 3 to 40 mm (mean size, 14.3 +/- 7.6 mm). The maximum tumor diameter was significantly greater for the IET group (17.9 +/- 6.5 mm) and the ET group (19.3 +/- 8.5 mm) than for the IT group (8.5 +/- 4.3 mm) (p < 0.001). The mean clinical growth index was determined as being 31.3 +/- 55.7 mm/yr for the total group. A significantly lower clinical growth index was found for the IT group (14.7 +/- 25.3 mm/yr) compared with the IET group (41.9 +/- 69.2 mm/yr) and the ET group (43.3 +/- 52.4 mm/yr) (p = 0.031). A significantly negative correlation between the clinical growth index and the age of the patients was noted for both the total group (p = 0.010) and the IET group (p = 0.017). A significantly negative correlation between the tumor size and the age of the patients was determined for the ET group (p = 0.22). CONCLUSIONS This study demonstrates a lower clinical growth index and smaller tumors in the older population, supporting data previously presented by extensive radiological studies. Our findings might provide a rationale for the consideration of the clinical growth index to estimate vestibular schwannoma growth rate.
Collapse
Affiliation(s)
- Marc Diensthuber
- Department of Otolaryngology, Hannover Medical University, Hannover, Germany
| | - Thomas Lenarz
- Department of Otolaryngology, Hannover Medical University, Hannover, Germany
| | - Timo Stöver
- Department of Otolaryngology, Hannover Medical University, Hannover, Germany
| |
Collapse
|
23
|
Herwadker A, Vokurka EA, Evans DGR, Ramsden RT, Jackson A. Size and Growth Rate of Sporadic Vestibular Schwannoma: Predictive Value of Information Available at Presentation. Otol Neurotol 2005; 26:86-92. [PMID: 15699725 DOI: 10.1097/00129492-200501000-00015] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND The current study examines the hypothesis that tumor growth rate in sporadic vestibular schwannoma could be in part predicted by data available at diagnosis, such as tumor volume, patient age, laterality, and sex. METHODS Tumor volumes and growth rates were calculated from serial magnetic resonance imaging data in a cohort of 50 patients (26 men and 24 women; mean age at presentation, 64.1 +/- 12.8 yr). Tumor volumes were measured using an algorithm that corrects for partial volume averaging errors and provides accurate estimates of tumor volume with known errors. RESULTS Examination of presentation data showed no relationship between tumor size at diagnosis and patient age, sex, or tumor laterality. Two measurements of tumor growth--absolute growth per annum and tumor volume doubling time--were studied, and neither showed any relationship with tumor size at presentation, patient age, tumor laterality, or sex. CONCLUSION The study represents a typical spectrum of patient ages and is of sufficient size in view of the distribution pattern of the variables to give a calculated statistical power in excess of 90% for each variable. This indicates that the clinical features available at presentation and diagnosis have no power to predict the expected behavior of sporadic vestibular schwannoma.
Collapse
Affiliation(s)
- Amit Herwadker
- Imaging Science and Biomedical Engineering, School of Medicine, University of Manchester, United Kingdom
| | | | | | | | | |
Collapse
|
24
|
Sandooram D, Grunfeld EA, McKinney C, Gleeson MJ. Quality of life following microsurgery, radiosurgery and conservative management for unilateral vestibular schwannoma. ACTA ACUST UNITED AC 2004; 29:621-7. [PMID: 15533149 DOI: 10.1111/j.1365-2273.2004.00881.x] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The best way to manage small and medium-sized vestibular schwannomas is currently a matter of heated debate. As these tumours are not immediately life-threatening, patients are invariably concerned about how management would affect their quality of life. Until now, no study has compared the three treatment modalities in terms of physical, psychological and social wellbeing. This study is based on a retrospective database analysis and postal questionnaire survey of unilateral vestibular schwannoma patients who had either been managed conservatively, or treated with microsurgery or radiosurgery. The results showed that: quality of life (measured by the Glasgow Benefit Inventory) deteriorated after microsurgery, particularly for small tumours; conservative management did not lead to a change in quality of life, and there was a trend towards poorer quality of life following radiosurgery. The findings suggest that a conservative management approach may be more appropriate for small tumours, and that patients who are due to undergo microsurgery or radiosurgery may benefit from counselling about the potential impact of treatment on quality of life.
Collapse
Affiliation(s)
- D Sandooram
- Department of Otolaryngology, Guy's & St Thomas' Hospital, London, UK.
| | | | | | | |
Collapse
|
25
|
Warren C, James LA, Ramsden RT, Wallace A, Baser ME, Varley JM, Evans DG. Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation. J Med Genet 2004; 40:802-6. [PMID: 14627667 PMCID: PMC1735326 DOI: 10.1136/jmg.40.11.802] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Schwannomas are benign tumours of the nervous system that are usually sporadic but also occur in the inherited disorder neurofibromatosis type 2 (NF2). The NF2 gene is a tumour suppressor on chromosome 22. Loss of expression of the NF2 protein product, merlin, is universal in both sporadic and NF2 related schwannomas. The GTPase signalling molecules RhoA and Rac1 regulate merlin function, but to date only mutation in the NF2 gene has been identified as a causal event in schwannoma formation. METHODS Comparative genomic hybridisation (CGH) was used to screen 76 vestibular schwannomas from 76 patients (66 sporadic and 10 NF2 related) to identify other chromosome regions that may harbour genes involved in the tumorigenesis. RESULTS The most common change was loss on chromosome 22, which was more frequent in sporadic than in NF2 related tumours. Importantly, eight tumours (10%) showed gain of copy number on chromosome 9q34. Each of the two NF2 patients who had received stereotactic radiotherapy had non-chromosome 22 changes, whereas only one of eight non-irradiated NF2 patients had any chromosome changes. Three tumours had gain on 17q, which has also been reported in malignant peripheral nerve sheath tumours that are associated with neurofibromatosis type 1. Other sites that were identified in three or fewer tumours were regions on chromosomes 10, 11, 13, 16, 19, 20, X, and Y. CONCLUSIONS These findings should be verified using techniques that can detect smaller genetic changes, such as microarray-CGH.
Collapse
Affiliation(s)
- C Warren
- Cancer Research UK Department of Cancer Genetics, The Paterson Institute for Cancer Research, Manchester, UK
| | | | | | | | | | | | | |
Collapse
|